Erika D'Agata1, Susan L Mitchell. 1. Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. edagata@bidmc.harvard.edu
Abstract
BACKGROUND: Nursing home residents with advanced dementia are at high risk of infections and antimicrobial exposure near the end of life. Detailed studies quantifying antimicrobial prescribing practices among these residents have not been performed. METHODS: A cohort of 214 residents with advanced dementia from 21 Boston-area nursing homes were followed up prospectively for 18 months or until death. We analyzed antimicrobial use, including type, indication, and quantity, by days of therapy per 1000 resident-days. RESULTS: During an average of 322 days of follow-up, 142 residents (66.4%) with advanced dementia received at least 1 course of antimicrobial therapy (mean [SD] number of courses per resident, 4.0 [3.7]). The mean (SD) number of days of therapy per 1000 resident-days for the entire cohort was 53.0 (4.3). Quinolones and third-generation cephalosporins were the most commonly prescribed antimicrobials, accounting for 38.3% and 15.2%, respectively, of 540 prescribed antimicrobial therapy courses. A respiratory tract infection was the most common indication (46.7% of all antimicrobial therapy courses). Among 99 decedents, 42 (42.4%) received antimicrobials during the 2 weeks before death, of which 30 of 72 courses (41.7%) were administered via the parenteral route. The number of decedents receiving antimicrobials (P < .001), the number of antimicrobials prescribed (P = .01), and the days of therapy per 1000 resident-days (P < .001) increased significantly as subjects approached death. CONCLUSIONS: Persons with advanced dementia are frequently exposed to antimicrobials, especially during the 2 weeks before death. The implications of this practice from the perspective of the individual treatment burden near the end of life and its contribution to the emergence of antimicrobial resistance in the nursing home setting need further evaluation.
BACKGROUND: Nursing home residents with advanced dementia are at high risk of infections and antimicrobial exposure near the end of life. Detailed studies quantifying antimicrobial prescribing practices among these residents have not been performed. METHODS: A cohort of 214 residents with advanced dementia from 21 Boston-area nursing homes were followed up prospectively for 18 months or until death. We analyzed antimicrobial use, including type, indication, and quantity, by days of therapy per 1000 resident-days. RESULTS: During an average of 322 days of follow-up, 142 residents (66.4%) with advanced dementia received at least 1 course of antimicrobial therapy (mean [SD] number of courses per resident, 4.0 [3.7]). The mean (SD) number of days of therapy per 1000 resident-days for the entire cohort was 53.0 (4.3). Quinolones and third-generation cephalosporins were the most commonly prescribed antimicrobials, accounting for 38.3% and 15.2%, respectively, of 540 prescribed antimicrobial therapy courses. A respiratory tract infection was the most common indication (46.7% of all antimicrobial therapy courses). Among 99 decedents, 42 (42.4%) received antimicrobials during the 2 weeks before death, of which 30 of 72 courses (41.7%) were administered via the parenteral route. The number of decedents receiving antimicrobials (P < .001), the number of antimicrobials prescribed (P = .01), and the days of therapy per 1000 resident-days (P < .001) increased significantly as subjects approached death. CONCLUSIONS:Persons with advanced dementia are frequently exposed to antimicrobials, especially during the 2 weeks before death. The implications of this practice from the perspective of the individual treatment burden near the end of life and its contribution to the emergence of antimicrobial resistance in the nursing home setting need further evaluation.
Authors: W E Trick; R A Weinstein; P L DeMarais; M J Kuehnert; W Tomaska; C Nathan; T W Rice; S K McAllister; L A Carson; W R Jarvis Journal: J Am Geriatr Soc Date: 2001-03 Impact factor: 5.562
Authors: Stephanie Stiel; Norbert Krumm; Martina Pestinger; Gabriele Lindena; Friedemann Nauck; Christoph Ostgathe; Lukas Radbruch; Frank Elsner Journal: Support Care Cancer Date: 2011-01-28 Impact factor: 3.603
Authors: Tessa van der Maaden; Simone A Hendriks; Henrica C W de Vet; Menno T Zomerhuis; Martin Smalbrugge; Elise P Jansma; Raymond T C M Koopmans; Cees M P M Hertogh; Jenny T van der Steen Journal: Drugs Aging Date: 2015-01 Impact factor: 3.923
Authors: Nick Daneman; Michael A Campitelli; Vasily Giannakeas; Andrew M Morris; Chaim M Bell; Colleen J Maxwell; Lianne Jeffs; Peter C Austin; Susan E Bronskill Journal: CMAJ Date: 2017-06-26 Impact factor: 8.262
Authors: Jane L Givens; Sara Spinella; Claire K Ankuda; Erika D'Agata; Michele L Shaffer; Daniel Habtemariam; Susan L Mitchell Journal: J Am Geriatr Soc Date: 2015-06-01 Impact factor: 5.562
Authors: Alyssa B Dufour; Michele L Shaffer; Erika M C D'Agata; Daniel Habtemariam; Susan L Mitchell Journal: J Am Geriatr Soc Date: 2015-11-28 Impact factor: 5.562
Authors: Halima Amjad; Donald Carmichael; Andrea M Austin; Chiang-Hua Chang; Julie P W Bynum Journal: JAMA Intern Med Date: 2016-09-01 Impact factor: 21.873